Key takeaways
- Grade C evidence: promising but limited RCTs for both bone density and arterial calcification benefits
- Recommended dose: 90–180 µg MK-7 per day, taken with a fatty meal alongside vitamin D
- The MK-7 form has a longer half-life than MK-4, making it the preferred choice for daily supplementation
- Critical interaction: vitamin K2 antagonises warfarin — never take without GP supervision if on anticoagulants
- Best suited to people already supplementing vitamin D who want to support calcium routing; unnecessary if on anticoagulants
What the evidence says
- Bone density supportC
- Arterial calcification reductionC
What Is Vitamin K2?
Vitamin K2 is a fat-soluble vitamin belonging to the broader vitamin K family. Unlike vitamin K1 (phylloquinone, found in leafy greens and primarily involved in blood clotting), K2 — particularly in its long-chain MK-7 (menaquinone-7) form — appears to play a distinct role in directing calcium to where the body actually wants it: bones and teeth, rather than soft tissue and arterial walls.
MK-7 is the form most studied for supplementation. It is found naturally in fermented foods — most abundantly in natto (fermented soybean), a Japanese staple — though most Western diets provide very little. MK-7 has a substantially longer biological half-life than MK-4 (another K2 subtype), meaning a daily dose of 90–180 µg achieves stable blood levels that MK-4 at comparable doses cannot.
Does It Work? The Evidence
Vitamin K2 carries a Grade C overall rating at Lift Republic. That means the mechanistic rationale is credible and there are supporting trials, but the body of evidence is limited in size, duration, and consistency. Here is what the research actually shows.
Bone Density — Grade C
The most plausible mechanism for K2's bone benefit runs through two vitamin K-dependent proteins: osteocalcin and Matrix Gla Protein (MGP). Osteocalcin, synthesised by osteoblasts (bone-building cells), must be carboxylated — activated by vitamin K — before it can effectively bind calcium in bone mineral. Without adequate K2, osteocalcin remains undercarboxylated and less functional.
A notable 2013 randomised controlled trial (Knapen et al., Osteoporosis International) followed 244 post-menopausal women for three years and found that 180 µg/day MK-7 significantly reduced the progression of age-related vertebral bone loss and improved bone strength indices compared to placebo. This trial, cited in our source list below, is the most robust single RCT in this space.
However, replication across different populations and durations is incomplete, and effect sizes are modest. The evidence is promising but cannot yet be called strong. Grade C is the honest rating.
Arterial Calcification — Grade C
The same carboxylation mechanism applies to Matrix Gla Protein (MGP), found in vascular smooth muscle. MGP is thought to be one of the most potent inhibitors of arterial calcification in the body — but only when adequately carboxylated via vitamin K2. Under-carboxylated MGP (ucMGP), a marker of K2 insufficiency, has been associated with greater arterial stiffness and calcification risk in observational studies.
Prospective and epidemiological data from the Rotterdam Study showed higher dietary K2 intake was inversely associated with coronary heart disease mortality and severe aortic calcification — but this is observational, not proof of causation. Intervention trials on arterial outcomes are few, shorter-term, and produce mixed results. Grade C reflects that reality: a plausible, interesting hypothesis backed by limited intervention evidence.
What K2 Does Not Do (Based on Current Evidence)
Vitamin K2 is often marketed with sweeping cardiovascular and anti-ageing claims. The current evidence does not support taking it for general energy, muscle performance, fat loss, or immunity. If those are your goals, other supplements have far stronger evidence: see creatine, vitamin D, and omega-3 fish oil.
How to Take It
Dose: 90–180 µg MK-7 per day. Most trials showing bone benefit used 180 µg.
Form: MK-7 is the preferred form for daily supplementation due to its longer half-life. MK-4 requires multiple doses per day at much higher amounts used in some clinical settings, which is not practical for general supplementation.
Timing: With a fatty meal — vitamin K2 is fat-soluble, so absorption is substantially better when consumed alongside dietary fat. Taking it alongside your vitamin D supplement is a sensible habit, since both are fat-soluble and the combination makes physiological sense (D promotes calcium absorption; K2 helps route that calcium appropriately).
Duration: Benefits are cumulative. The most meaningful bone-density data comes from trials lasting 1–3 years, not weeks. Do not expect rapid changes.
Who Should Take It — and Who Shouldn't
Most likely to benefit:
- Post-menopausal women concerned about bone density
- Older adults (over 50) already supplementing vitamin D
- People with low natto/fermented-food intake who want additional insurance on calcium routing
- Those with elevated undercarboxylated MGP markers (if tested)
If you are already following a solid training programme and eating well, vitamin K2 is a minor, speculative addition — not a foundation supplement. For bone health that actually moves the needle, resistance training and adequate protein matter far more. If you need help building that foundation, take the free Blueprint quiz or book a free consultation.
Should not take:
- Anyone on warfarin (or other vitamin K antagonist anticoagulants): this is the single most important contraindication. Warfarin works by blocking vitamin K-dependent clotting factors. Adding a vitamin K2 supplement reduces warfarin's effect in an unpredictable, potentially dangerous way — raising the risk of clots, stroke, or pulmonary embolism. This is a hard stop. Do not self-supplement; speak to your GP or anticoagulant clinic.
- Pregnant or breastfeeding women (consult a GP first — the evidence in these groups is insufficient)
- Under-18s without medical supervision
Safety & Interactions
At the dosing range of 90–180 µg MK-7/day, vitamin K2 appears well tolerated in otherwise healthy adults. No significant side effects have been consistently reported in trials at these doses.
However, the warfarin/anticoagulant interaction is the dominant safety consideration and cannot be overstated. Even modest increases in vitamin K intake can shift INR (International Normalised Ratio) readings, which anticoagulant clinics monitor closely. If you are on warfarin or any other vitamin K antagonist anticoagulant, get specific medical advice before adding any vitamin K supplement. Note that rivaroxaban and apixaban are a different drug class (factor Xa inhibitors / NOACs) whose anticoagulant effect is not modulated by vitamin K — however, anyone on any anticoagulant should consult their GP before starting new supplements.
For everyone else: buy a tested product from a reputable manufacturer. Vitamin K2 does not currently fall under Informed-Sport's athlete-certification programme, but general third-party testing for identity, potency, and heavy metals is worthwhile — look for products verified by independent labs (e.g., NSF, Labdoor, or a UKAS-accredited lab).
General information, not medical advice — check with a GP or pharmacist before starting, especially if pregnant, breastfeeding, under 18, or on medication.
How to Buy It Well
- Specify MK-7, not just K2. MK-4 products exist but require far higher doses and multiple daily administrations to match what MK-7 achieves with 90–180 µg once daily.
- Check the dose. Some products underdose at 45 µg — most trials used 90–180 µg. Read the label.
- Third-party tested. Choose a supplier with independent quality verification. A fat-soluble vitamin stored poorly can degrade; freshness and proper storage matter.
- Stack sensibly. Vitamin K2 combined with vitamin D is the most logical pairing — D without K2 is the more common pattern, but the combination is supported by physiological logic.
The Verdict
Vitamin K2 (MK-7) earns a Situational verdict with a Grade C evidence rating. The science behind its role in calcium routing — through osteocalcin and MGP carboxylation — is sound, and there is genuine trial data for bone density in post-menopausal women. The arterial calcification story is plausible but less proven.
It is not a must-have. It is not a skip, either. If you are already supplementing vitamin D, are post-menopausal or over 50, and want to add a low-cost, low-risk layer of bone and vascular support, 90–180 µg MK-7/day is a reasonable addition. If you are on warfarin, it is an absolute no without GP sign-off.
Supplements like this are the final 5%. Diet, training, sleep, and consistency are the other 95% — and that is exactly what a coach helps you nail. Book a free consultation and let us build the programme that actually moves the needle.
Supplements are about 5% of the result. A coach gets the other 95% right.
Book a free consultationSafety & interactions
Generally well tolerated at 90–180 µg MK-7/day. The critical safety flag is the warfarin interaction: vitamin K2 reduces warfarin's anticoagulant effect, raising clotting risk. Anyone on anticoagulants must not self-supplement. General information, not medical advice — check with a GP or pharmacist before starting, especially if pregnant, breastfeeding, under 18, or on medication.
Avoid / check first if: Taking warfarin or any vitamin K antagonist anticoagulant — vitamin K2 directly opposes its action. Speak to your GP before starting.
General information, not medical advice. Check with a GP or pharmacist before starting a supplement — especially if you are pregnant, breastfeeding, under 18, or taking any medication.
Sources & further reading
- MK-7 bone RCT (Knapen et al., Osteoporosis International 2013) — PubMed / Osteoporosis International
- Rotterdam Study — dietary K2 and coronary heart disease (Geleijnse et al., J Nutr 2004) — PubMed / Journal of Nutrition
- Examine — Vitamin K — Examine
Citations are provided for transparency. This is general information, not medical advice — always consult a qualified professional about your own circumstances.